BDNF Gp120 transgenic mice IL-1b Light-dark transition Open field Prepulse inhibition tPA TNFa a b s t r a c t Human immunodeficiency virus type 1 (HIV) infection of the brain produces cognitive and motor disorders. In addition, HIV positive individuals exhibit behavioral alterations, such as apathy, and a decrease in spontaneity or emotional responses, typically seen in anxiety disorders. Anxiety can lead to psychological stress, which has been shown to influence HIV disease progression. These considerations underscore the importance of determining if anxiety in HIV is purely psychosocial, or if by contrast, there are the molecular cascades associated directly with HIV infection that may mediate anxiety. The present study had two goals: (1) to determine if chronic exposure to viral proteins would induce anxiety-like behavior in an animal model and (2) to determine if this exposure results in anatomical abnormalities that could explain increased anxiety. We have used gp120 transgenic mice, which display behavior and molecular deficiencies similar to HIV positive subjects with cognitive and motor impairments. In comparison to wild type mice, 6 months old gp120 transgenic mice demonstrated an anxiety like behavior measured by open field, light/dark transition task, and prepulse inhibition tests. Moreover, gp120 transgenic mice have an increased number of spines in the amygdala, as well as higher levels of brain-derived neurotrophic factor and tissue plasminogen activator when compared to age-matched wild type. Our data support the hypothesis that HIV, through gp120, may cause structural changes in the amygdala that lead to maladaptive responses to anxiety.
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Introduction
Human immunodeficiency virus (HIV) infection of the brain often leads to neurological deficits characterized by cognitive impairments and motor deficits, termed HIV-associated neurological disorders (HAND) (Chan and Brew, 2014; Heaton et al., 2011; Tan and McArthur, 2012) . Psychiatric and anxiety symptoms are also very common in individuals with HIV (Bing et al., 2001; Kemppainen et al., 2013) . Moreover, people living with HIV are vulnerable to suicidal ideation and behavior. Indeed, the suicide rates are three times higher than in the general population (Carrico, 2010) . In addition, anxiety-induced stress has also been shown to promote viral replication, reduce immune responses and interfere with antiretroviral therapy [reviewed in (Riley and Kalichman, 2015) ]. Individuals with anxiety and psychiatric comorbidities have lower adherence to HIV medications, decreased quality of life, greater health care utilization, and poorer prognosis when compared to individuals without psychiatric disorders (Cohen et al., 2007; Weaver et al., 2005) . Thus, the importance of understanding how HIV causes anxiety syndrome is paramount.
Anxiety symptoms are usually attributed to preexisting predisposition, trauma or abuse, or to the diagnosis itself. Initial diagnosis with HIV is associated with significant stress, as is the prospect of disclosure of diagnosis and having to live with HIV (Hult et al., 2012; Olley et al., 2005) . While the general diagnosis and prevalence of anxiety and depression vary across cultures (LewisFernandez et al., 2010) , these symptoms have been widely reported in HIV-positive patient cohorts across the globe (Kee et al., 2015; Mutumba et al., 2015; Tesfaye and Bune, 2014) . This cross-cultural prevalence raises the possibility that in addition to
